Lung Cancer: ACS Atlas of Clinical Oncology (American Cancer Society Atlas of Clinical Oncology)
Nature Publishing Group (Free subscription) | 28/10/2009
We thank Dr. Gozzetti for his comments about a possible delayed clinical response to bortezomib instead of chemosensitivity restoration by bortezomib because the response to bortezomib may sometimes be delayed. Moreover, documentation of multi-drug resistance (MDR) would have clarified this postulation before and after Vel–CMP
Nature Publishing Group (Free subscription) | 28/10/2009
I read with great interest the Case Study by Chim and colleagues (Restoration of chemosensitivity by bortezomib: implications for refractory myeloma.
Nature Publishing Group (Free subscription) | 28/10/2009
Background. A 61-year-old patient with no relevant medical or family history presented with a 2 month history of refractory dry cough that led to the diagnosis of typical carcinoid tumor of the lung metastatic to the mediastinal lymph nodes and liver. She initially received
Nature Publishing Group (Free subscription) | 28/10/2009
Maintenance therapy aims to sustain a state of ongoing disease remission. This article discusses the results of randomized trials that suggest that specific subgroups of patients with follicular lymphoma should receive maintenance therapy with rituximab.
Nature Publishing Group (Free subscription) | 28/10/2009
The monoclonal antibody, rituximab, is used to treat lymphomas. This article discusses the results of randomized trials that suggest patients with follicular lymphoma should not receive rituximab maintenance therapy.
Nature Publishing Group (Free subscription) | 28/10/2009
Pooled analyses from the Adjuvant Treatment of Colon Cancer trial suggest that most patients with stage III colon cancer develop recurrence within the first 3 years following treatment. Improved disease-free survival and improved overall survival were observed for such patients who were treated with adjuvant combination therapy of 5-fluorouracil, leucovorin and oxaliplatin versus those treated with...
Nature Publishing Group (Free subscription) | 28/10/2009
Imaging is performed in patients with early stage non-small-cell lung cancer (NSCLC) for disease staging and to identify the patients most likely to benefit from surgery. Two recent randomized trials compared conventional staging plus PET with conventional staging alone in patients with NSCLC. Patients who underwent PET were more likely to avoid futile thoracic surgery.
Nature Publishing Group (Free subscription) | 28/10/2009
Pathology: Prostate cancer—personalized response prediction Nature Reviews Clinical Oncology 6, 618 (2009). doi:10.1038/nrclinonc.2009.156 Author: Vessela Vassileva
Nature Publishing Group (Free subscription) | 28/10/2009
Hematology: Ipilimumab of benefit in unresectable melanoma Nature Reviews Clinical Oncology 6, 618 (2009). doi:10.1038/nrclinonc.2009.155 Author: Mandy Aujla
Nature Publishing Group (Free subscription) | 28/10/2009
Targeted therapies: Denosumab benefits men on long-term ADT Nature Reviews Clinical Oncology 6, 617 (2009). doi:10.1038/nrclinonc.2009.158 Author: Mandy Aujla
Nature Publishing Group (Free subscription) | 28/10/2009
Hematology: Hodgkin lymphoma survivors: high risk of stroke and TIA Nature Reviews Clinical Oncology 6, 617 (2009). doi:10.1038/nrclinonc.2009.152 Author: Lisa Hutchinson
Nature Publishing Group (Free subscription) | 28/10/2009
Gefitinib efficacy in adenocarcinoma Nature Reviews Clinical Oncology 6, 617 (2009). doi:10.1038/nrclinonc.2009.151 Author: Lisa Hutchinson
Nature Publishing Group (Free subscription) | 28/10/2009
Micrometastases and breast cancer Nature Reviews Clinical Oncology 6, 616 (2009). doi:10.1038/nrclinonc.2009.157 Author: Mandy Aujla
Nature Publishing Group (Free subscription) | 28/10/2009
Medical oncology: T-cell infiltrate predicts long-term survival in CRC Nature Reviews Clinical Oncology 6, 616 (2009). doi:10.1038/nrclinonc.2009.153 Author: Lisa Hutchinson
Nature Publishing Group (Free subscription) | 28/10/2009
Pathology: Protein kinase A predicts response to radiation and androgen deprivation therapy Nature Reviews Clinical Oncology 6, 615 (2009). doi:10.1038/nrclinonc.2009.154 Author: Vessela Vassileva
Videos